KOTAI Biotechnologies Overview
- Year Founded
-
2016

- Status
-
Acquired/Merged
- Employees
-
20

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$7.1M
KOTAI Biotechnologies General Information
Description
Developer of a structural modeling and analysis platform for immune cell receptors designed to aid in better drug discovery. The company leverages algorithms and data to reveal the structure and function of immune cell receptors from blood to help in better diagnosis, prognosis, and drug efficacy prediction, enabling pharmaceutical companies to bring efficacy to drug discovery.
Contact Information
Website
www.kotai-bio.com(Operating Subsidiary)
Corporate Office
- 2nd Floor, Building B, Office For Industry-University Co-Creation
- Osaka University, 2-1 Yamadaoka, Suita
- Osaka, 565-0871
- Japan
Corporate Office
- 2nd Floor, Building B, Office For Industry-University Co-Creation
- Osaka University, 2-1 Yamadaoka, Suita
- Osaka, 565-0871
- Japan
KOTAI Biotechnologies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Merger/Acquisition | 31-Jul-2023 | $7.1M | Completed | Generating Revenue | ||
3. Later Stage VC (Series C) | 28-Oct-2020 | Completed | Generating Revenue | |||
2. Early Stage VC (Series B) | 28-Aug-2017 | $1.83M | $2.32M | Completed | Startup | |
1. Early Stage VC (Series A) | 21-Oct-2016 | $487K | $487K | Completed | Startup |
KOTAI Biotechnologies Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
C preferred | ||||||||
B preferred | ||||||||
A preferred | 2,500 | $189.86 | $189.86 | 1x | $189.86 | 7.37% |
KOTAI Biotechnologies Patents
KOTAI Biotechnologies Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2022187385-A | Antibodies against sars-cov-2 spike protein | Pending | 07-Jun-2021 | ||
EP-4310171-A1 | Novel medical technique using follicular t-cells | Pending | 16-Mar-2021 | ||
EP-4310095-A1 | Follicular helper t (tfh) cells specific to sars-cov-2 virus | Pending | 16-Mar-2021 | ||
US-20240159738-A1 | Novel medical technique using follicular t-cells | Pending | 16-Mar-2021 | ||
US-20240309051-A1 | Follicular helper t (tfh) cells specific to sars-cov-2 virus | Pending | 16-Mar-2021 | A61K39/12 |
KOTAI Biotechnologies Signals
KOTAI Biotechnologies Former Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Amashin-Shinkin | Venture Capital | Minority | ||
Japan Agency for Medical Research and Development | Government | Minority | ||
Minato Growing Enterprises | Venture Capital | Minority | ||
New Energy and Industrial Technology Development Organization | Government | Minority | ||
Nippon Venture Capital | Corporate Venture Capital | Minority |
KOTAI Biotechnologies FAQs
-
When was KOTAI Biotechnologies founded?
KOTAI Biotechnologies was founded in 2016.
-
Where is KOTAI Biotechnologies headquartered?
KOTAI Biotechnologies is headquartered in Osaka, Japan.
-
What is the size of KOTAI Biotechnologies?
KOTAI Biotechnologies has 20 total employees.
-
What industry is KOTAI Biotechnologies in?
KOTAI Biotechnologies’s primary industry is Biotechnology.
-
Is KOTAI Biotechnologies a private or public company?
KOTAI Biotechnologies is a Private company.
-
What is the current valuation of KOTAI Biotechnologies?
The current valuation of KOTAI Biotechnologies is
. -
What is KOTAI Biotechnologies’s current revenue?
The current revenue for KOTAI Biotechnologies is
. -
How much funding has KOTAI Biotechnologies raised over time?
KOTAI Biotechnologies has raised $4.79M.
-
Who are KOTAI Biotechnologies’s investors?
Amashin-Shinkin, Japan Agency for Medical Research and Development, Minato Growing Enterprises, New Energy and Industrial Technology Development Organization, and Nippon Venture Capital are 5 of 8 investors who have invested in KOTAI Biotechnologies.
-
When was KOTAI Biotechnologies acquired?
KOTAI Biotechnologies was acquired on 31-Jul-2023.
-
Who acquired KOTAI Biotechnologies?
KOTAI Biotechnologies was acquired by Sanyo Trading Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »